<DOC>
	<DOCNO>NCT02354781</DOCNO>
	<brief_summary>The propose clinical trial outgrowth safety record functional improvement see BMD follistatin gene therapy trial . In study investigator propose inject AAV1.CMV.huFS344 total dose 2.4E12 vg/kg six DMD patient . This dose divide gluteal muscle , quadriceps tibialis anterior . This wider distribution vector give BMD patient , overall improve distance walk 6MWT without adverse event related viral transduction single muscle .</brief_summary>
	<brief_title>Clinical Intramuscular Gene Transfer rAAV1.CMV.huFollistatin344 Trial Patients With Duchenne Muscular Dystrophy</brief_title>
	<detailed_description>The primary objective study safety endpoint include hematology , serum chemistry , urinalysis , immunologic response rAAV1 follistatin , report history observation symptom . Efficacy measure use secondary outcome include distance walk 6MWT , functional test PT , life quality questionnaire , MRI , EIM , muscle biopsy . Subject follow visit day 7 , 14 , 30 , 45 , 60 , 90 , 180 9,12 , 18 24 month post-gene transfer .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Age 7 old Confirmed DMD gene mutation Impaired muscle function base clinical evidence include difficulty climb stair , get floor ( Gowers ' sign ) , weakness individual muscle extremity Males ethnic group eligible Ability cooperate study procedure include muscle testing . Willingness sexually active subject reproductive capacity practice reliable method contraception Subjects must stable dose prednisone three month time enrollment start oral dose daily prednisone regimen 30 day prior gene transfer . Study participant continue prednisone post gene transfer unless adverse event warrant prednisone taper withdrawal . Active viral infection base clinical observation . The presence DMD gene mutation without weakness loss function Symptoms sign cardiomyopathy , include : Dyspnea exertion , pedal edema , shortness breath upon lie flat , rales base lung Echocardiogram ejection fraction 40 % Serological evidence HIV infection , Hepatitis A , B C infection Diagnosis ( ongoing treatment ) autoimmune disease Concomitant illness requirement chronic drug treatment opinion PI create unnecessary risk gene transfer Subjects rAAV1 bind antibody titer &gt; 1:50 determined ELISA immunoassay Abnormal laboratory value liver , kidney , CBC , clinically significant range , base upon normal value Nationwide Children 's Hospital Laboratory</criteria>
	<gender>Male</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>DMD</keyword>
	<keyword>muscular dystrophy</keyword>
	<keyword>Follistatin</keyword>
</DOC>